A matching-adjusted indirect comparison of acalabrutinib versus zanubrutinib in relapsed or refractory chronic lymphocytic leukemia

Authors
Publication date
10 October 2023
Publisher
Doi

    Abstract

    Video abstract for our matching-adjusted indirect comparison of acalabrutinib versus zanubrutinib in relapsed or refractory chronic lymphocytic leukemia</p

      Similar works

      Full text

      thumbnail-image

      Available Versions

      FigShare

      redirect
      oaioai:figshare.com:article/24250...
      Last time updated on 04/11/2023